middle.news
Actinogen Advances Alzheimer's Trial with Positive Regulatory Feedback and Strong Cash Position
10:03am on Thursday 30th of July, 2026 AEST
•
Biotechnology
Read Story
Actinogen Advances Alzheimer's Trial with Positive Regulatory Feedback and Strong Cash Position
10:03am on Thursday 30th of July, 2026 AEST
Key Points
XanaMIA trial on schedule for November results
88% participant rollover to open-label extension
Positive EMA advice aligns with prior FDA feedback
Peer-reviewed antidepressant activity published
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE